Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab
Abstract Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”. Determining which patients will benefit remains an important clinical goal. In a non-inflamed tumor mouse model, we found that PD-L1 was highly expressed on antigen-presenting cells (APCs) especially o...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-07-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-93113-y |
id |
doaj-4b94adbd323b4bf69ee418f876c26582 |
---|---|
record_format |
Article |
spelling |
doaj-4b94adbd323b4bf69ee418f876c265822021-07-11T11:28:13ZengNature Publishing GroupScientific Reports2045-23222021-07-0111111510.1038/s41598-021-93113-yBoth T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumabToshiki Iwai0Masamichi Sugimoto1Namrata S. Patil2Daniel Bower3Miho Suzuki4Chie Kato5Keigo Yorozu6Mitsue Kurasawa7David S. Shames8Osamu Kondoh9Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd.Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd.Oncology Biomarker Development, Genentech, Inc.Oncology Biomarker Development, Genentech, Inc.Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd.Research Division, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd.Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd.Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd.Oncology Biomarker Development, Genentech, Inc.Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd.Abstract Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”. Determining which patients will benefit remains an important clinical goal. In a non-inflamed tumor mouse model, we found that PD-L1 was highly expressed on antigen-presenting cells (APCs) especially on CD103+ CD11c+ dendritic cells in tumor-draining lymph nodes (dLNs), suppressing T-cell priming by APCs. In this model, anti-PD-L1 antibodies enhanced T-cell priming and increased CXCR3+ activated T-cells in dLNs, which was followed by the trafficking of T-cells to tumors in response to CXCR3 ligands. As predictive biomarker, each APCs-related gene expression (AP score) alone or T-cells trafficking-related chemokine gene expression (T score) alone were still less than perfect among the 17 mouse models examined. However a combining score of AP score and T score (AP/T score) precisely identified anti-PD-L1-sensitive tumors. In the phase 3 trial of atezolizumab vs docetaxel in advanced NSCLC patients (OAK), the AP/T score could identify atezolizumab-treated NSCLC patients who achieved significant improvement in overall survival. This biomarker concept would be a clinically valuable for prediction of anti-PD-L1 antibody efficacy.https://doi.org/10.1038/s41598-021-93113-y |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Toshiki Iwai Masamichi Sugimoto Namrata S. Patil Daniel Bower Miho Suzuki Chie Kato Keigo Yorozu Mitsue Kurasawa David S. Shames Osamu Kondoh |
spellingShingle |
Toshiki Iwai Masamichi Sugimoto Namrata S. Patil Daniel Bower Miho Suzuki Chie Kato Keigo Yorozu Mitsue Kurasawa David S. Shames Osamu Kondoh Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab Scientific Reports |
author_facet |
Toshiki Iwai Masamichi Sugimoto Namrata S. Patil Daniel Bower Miho Suzuki Chie Kato Keigo Yorozu Mitsue Kurasawa David S. Shames Osamu Kondoh |
author_sort |
Toshiki Iwai |
title |
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab |
title_short |
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab |
title_full |
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab |
title_fullStr |
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab |
title_full_unstemmed |
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab |
title_sort |
both t cell priming in lymph node and cxcr3-dependent migration are the key events for predicting the response of atezolizumab |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2021-07-01 |
description |
Abstract Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”. Determining which patients will benefit remains an important clinical goal. In a non-inflamed tumor mouse model, we found that PD-L1 was highly expressed on antigen-presenting cells (APCs) especially on CD103+ CD11c+ dendritic cells in tumor-draining lymph nodes (dLNs), suppressing T-cell priming by APCs. In this model, anti-PD-L1 antibodies enhanced T-cell priming and increased CXCR3+ activated T-cells in dLNs, which was followed by the trafficking of T-cells to tumors in response to CXCR3 ligands. As predictive biomarker, each APCs-related gene expression (AP score) alone or T-cells trafficking-related chemokine gene expression (T score) alone were still less than perfect among the 17 mouse models examined. However a combining score of AP score and T score (AP/T score) precisely identified anti-PD-L1-sensitive tumors. In the phase 3 trial of atezolizumab vs docetaxel in advanced NSCLC patients (OAK), the AP/T score could identify atezolizumab-treated NSCLC patients who achieved significant improvement in overall survival. This biomarker concept would be a clinically valuable for prediction of anti-PD-L1 antibody efficacy. |
url |
https://doi.org/10.1038/s41598-021-93113-y |
work_keys_str_mv |
AT toshikiiwai bothtcellpriminginlymphnodeandcxcr3dependentmigrationarethekeyeventsforpredictingtheresponseofatezolizumab AT masamichisugimoto bothtcellpriminginlymphnodeandcxcr3dependentmigrationarethekeyeventsforpredictingtheresponseofatezolizumab AT namrataspatil bothtcellpriminginlymphnodeandcxcr3dependentmigrationarethekeyeventsforpredictingtheresponseofatezolizumab AT danielbower bothtcellpriminginlymphnodeandcxcr3dependentmigrationarethekeyeventsforpredictingtheresponseofatezolizumab AT mihosuzuki bothtcellpriminginlymphnodeandcxcr3dependentmigrationarethekeyeventsforpredictingtheresponseofatezolizumab AT chiekato bothtcellpriminginlymphnodeandcxcr3dependentmigrationarethekeyeventsforpredictingtheresponseofatezolizumab AT keigoyorozu bothtcellpriminginlymphnodeandcxcr3dependentmigrationarethekeyeventsforpredictingtheresponseofatezolizumab AT mitsuekurasawa bothtcellpriminginlymphnodeandcxcr3dependentmigrationarethekeyeventsforpredictingtheresponseofatezolizumab AT davidsshames bothtcellpriminginlymphnodeandcxcr3dependentmigrationarethekeyeventsforpredictingtheresponseofatezolizumab AT osamukondoh bothtcellpriminginlymphnodeandcxcr3dependentmigrationarethekeyeventsforpredictingtheresponseofatezolizumab |
_version_ |
1721308999265026048 |